Trials / Completed
CompletedNCT01860482
The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD
An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell® Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of Newrabell® Tab. in patients with refractory reflux esophagitis to the prior standard PPIs regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Newrabell® Tablet 10mg |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2013-05-22
- Last updated
- 2015-09-24
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01860482. Inclusion in this directory is not an endorsement.